Hot flush pill gets green light for UK use
The treatment, made by Bayer, can be given to women who have vasomotor symptoms, also known as hot flushes, as an alternative to hormone replacement therapy (HRT).
HRT can help relieve most menopause and perimenopause symptoms, including hot flushes.
But not all patients want or are able to take hormone treatments.
At present elinzanetant is not available on the NHS but the green light from the MHRA means that it can be purchased privately in the UK.
It is to be considered by the NHS spending watchdog, the National Institute for Health and Care Excellence.
Hot flushes and night sweats are one of the most common symptoms of menopause.
It is understood that as oestrogen levels decline around menopause, the body's temperature regulation system can be disrupted when certain brain cells become overactive.
The new treatment, which is a non-hormonal medication, works by calming these signals in the brain.
Clinical trial data showed that the drug was safe and well tolerated and reduced hot flushes compared with a dummy drug, also known as a placebo.
You may not have reached #menopause if you're experiencing headaches, night sweats, weight gain, anxiety and depression – but you may be #perimenopausal. Take a look on our website for more information 👉 https://t.co/hw2P09ZPA6 pic.twitter.com/zvbXIWXh3C
— Patient (@patient) May 22, 2023
It was also linked to fewer sleep disturbances and women taking it reported a better quality of life compared with those taking the placebo.
'Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life,' said Julian Beach, the MHRA's interim executive director of healthcare quality and access.
'We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA's standards for safety, quality and effectiveness.
'Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies.
'As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.'
Women usually go through the menopause when they are aged between 45 and 55, though it can start sooner.
During the menopause a woman's periods stop due to lower hormone levels.
Menopause and perimenopause can cause symptoms including anxiety, mood swings, brain fog, hot flushes and irregular periods.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
an hour ago
- Powys County Times
‘Outdated guidance' sees thousands at risk of prostate cancer ‘overtreatment'
Up to 5,000 men every year could avoid unnecessary treatment for prostate cancer if 'outdated' guidelines reflected latest evidence, a charity has said. Overtreatment of the disease can lead to side effects such as erectile dysfunction or incontinence, according to Prostate Cancer UK. Experts suggest closely monitoring certain patients can be the 'best' option for men whose cancer is unlikely to progress, although out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a 'wild west'. There are around 55,000 new cases of prostate cancer diagnosed in the UK every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. These men benefit from being closely monitored with blood tests and scans, which is known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it has not been updated since 2021, according to Prostate Cancer UK. Freedom of information (FOI) request analysis by the charity found around one in four (24%) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: 'To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. 'Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. 'Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. 'We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough.' The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. However, there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: 'Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. 'But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. 'This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. 'Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work.' The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: 'We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. 'They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. 'We are updating our prostate cancer guideline, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating.'
North Wales Chronicle
2 hours ago
- North Wales Chronicle
Expectant mothers to bypass GP and go straight to midwife
Traditionally, mothers-to-be made an appointment with their family doctor to tell them the news before being booked in with their midwife. And in recent years, online self-referral has been introduced by local health bodies. But NHS leaders said that only half of expectant mothers were using these services directly, with many going 'unnecessarily' to their GP to access maternity care. Women will now be able to refer themselves to local maternity services 'at the touch of a button' via which will give them faster first appointments, NHS England said. It is hoped that the move could free up tens of thousands of appointments for overstretched GPs. Officials stressed that women can still see a GP if they would like to, adding that some with long-term health conditions will need to discuss changes to their care or treatment plans with a doctor. Just found out you're pregnant? You can now refer yourself to maternity services – no need to see your GP first. It's quick, simple, and gets your care started early. Start your pregnancy journey at UHS here: #MaternityMatters — University Hospital Southampton 💙 (@UHSFT) July 9, 2025 Health officials said that first midwife appointments are 'vital', but only 62% of these happened within the first 10 weeks of pregnancy in 2023/24. There are around 600,000 babies born each year in England and Wales. NHS England said that it is estimated that the new service could lead to 180,000 fewer calls to GPs and up to 30,000 fewer general practice appointments each year. But around a quarter of local health bodies are yet to 'connect' to the national service, it added, with pregnant women in these areas able to self-refer via local trust sites. In 2024, there were 594,677 live births in England and Wales, an increase of 3,605 (0.6%) compared with 2023 (591,072). This is the first increase since 2021, although it is smaller than the 1.8% increase from 2020 to 2021 ➡️ — Office for National Statistics (ONS) (@ONS) July 1, 2025 'It's so important that newly pregnant women get the support they need as soon as possible, so this new tool makes it easier than ever to book that all-important first maternity care appointment,' said Kate Brintworth, NHS chief midwife. 'Making this process simpler at the touch of a button is a vital step in empowering women to take control of their pregnancy journey right from the very start and improving access to timely, personalised care.' Dr Claire Fuller, NHS England's national medical director, said: 'GPs are available for any pregnant women who have concerns about their pregnancy they need to discuss, or other health conditions that need monitoring, but in many cases, GP teams don't need to be the first point of contact when someone finds out they're pregnant. 'This quick and easy tool can help ease pressure on practice teams, who won't need to make the referral themselves, and by freeing up that time there will hopefully be a benefit for other patients who are looking to make an appointment with their GP.' Health and Social Care Secretary Wes Streeting said: 'Early pregnancy should be about joy and excitement – not wrestling with NHS bureaucracy to book a midwife appointment. 'That's why we've overhauled the online referral system. No more endless phone calls or form-filling. Just a simple online service that lets you book those crucial first appointments with a few clicks.' Abbie Aplin, director of maternity improvement and partnerships at the Royal College of Midwives, said: 'Giving women more control and more agency over their care during pregnancy, labour, birth and the postnatal period can only be a good thing. 'Midwives are best placed to support women to make informed choices about their care, so the earlier the better in terms of access. 'We do have to be mindful, though, of those who don't have easy access to smartphones and technology. 'We already see significant inequalities of outcome for women living with social deprivation so the NHS needs to ensure that those gaps aren't widened yet further.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'It's vital that women are able to access the most appropriate person-centred care from the earliest stages and throughout their pregnancy. 'In most cases this will be provided by midwife teams, so this initiative, as long as it is implemented correctly, makes sense. 'It's important that women in early pregnancy still know they can come to their GP directly with any concerns about their pregnancy or health – and for women with existing health conditions, we would advise that they remain in contact with their GP as their pregnancy progresses. 'Anyone that has any issues accessing online referrals can also still be referred to appropriate maternity care through their GP practice.'
North Wales Chronicle
2 hours ago
- North Wales Chronicle
‘Outdated guidance' sees thousands at risk of prostate cancer ‘overtreatment'
Overtreatment of the disease can lead to side effects such as erectile dysfunction or incontinence, according to Prostate Cancer UK. Experts suggest closely monitoring certain patients can be the 'best' option for men whose cancer is unlikely to progress, although out-of-date guidance from the National Institute of Health and Care Excellence (Nice) on how this is implemented has created a 'wild west'. There are around 55,000 new cases of prostate cancer diagnosed in the UK every year. However, in some cases, the cancer is slow-growing and unlikely to ever cause the patient harm. These men benefit from being closely monitored with blood tests and scans, which is known as active surveillance. Nice guidance on active surveillance is designed to advise specialists on how to implement monitoring and which men should be monitored. However, it has not been updated since 2021, according to Prostate Cancer UK. Freedom of information (FOI) request analysis by the charity found around one in four (24%) of hospitals rely on Nice guidance alone to implement active surveillance. It also found 35 hospitals have created their own guidelines, which Prostate Cancer UK warned can lead to inconsistency and confusion among medics. The charity is now repeating its call for Nice to update its guidance on active surveillance, claiming it could help up to 5,000 men a year avoid overtreatment. It also claims the outdated guidance is hindering a screening programme for prostate cancer. Amy Rylance, assistant director of health improvement at Prostate Cancer UK, said: 'To reduce the harm caused by prostate cancer and build the foundations for a screening programme, we need to both save lives and prevent unnecessary treatment but official guidelines still haven't caught up with the clinical evidence. 'Concerns about overtreatment are a major reason the UK does not routinely screen for prostate cancer, despite it being the most common cancer in England. 'Acting on latest research that shows more men can safely opt for monitoring instead of treatment will reduce overtreatment and the harm it causes men. 'We asked Nice to update their active surveillance guidance two years ago, but our request was rejected. Now we have evidence this is potentially affecting thousands of men. Enough is enough.' The NHS uses a prostate-specific antigen (PSA) blood test to check for prostate conditions including prostate cancer or an enlarged prostate. Routine PSA testing is not currently offered on the NHS, but patients may be offered a PSA test if a GP suspects they have prostate cancer, while men over 50 can request a test from their GP even if they do not have symptoms. However, there have been calls to roll the test out across the health service, although some argue widespread use could identify cases which may not have caused problems or needed treatment. Vincent Gnanapragasam, a professor of urology at the University of Cambridge, said: 'Active surveillance is the best treatment option for men whose cancer is unlikely to progress or cause them problems in their lifetime. 'But Nice's outdated guidelines have created a deeply concerning wild west on how surveillance is implemented by different healthcare teams. 'This inconsistency is resulting in a lack of confidence from patients in surveillance, who may instead opt to have treatment they may not have ever needed, risking harmful side effects. 'Programmes for active surveillance that are standardised and individualised to a man's risk factors have been tested and proven to work.' The UK's National Screening Committee is currently assessing whether a national screening programme for prostate cancer should be rolled out. A Nice spokesperson said: 'We are committed to ensuring our guidelines continue to reflect the best available evidence and give patients the best possible outcomes. 'They are developed by an independent committee, including NHS clinical experts, and are kept under review to ensure they remain current. 'We are updating our prostate cancer guideline, including a review of the recommendations around active surveillance, and will be assessing whether our suspected cancer guideline recommendations around age-related thresholds for PSA tests for prostate cancer for onwards referral from primary care require updating.'
